EBS up +6.49% percent right now. $EBS High is at 24.46 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 2:54 PM

EBS up +6.49% percent right now. $EBS High is at 24.46 and the Low 23.32 with current volume of 558,700.

Recent News posted below.

EBS Emergent Biosolutions Recent Headline News

Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 23.95 (+1.46)

Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 23.95 (+1.46)

Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included:
EBS: 23.95 (+1.46)

3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 23.95 (+1.46), NLNK: 32.15 (-2.54), TEVA: 57.70 (-1.02), AMRI: 16.84 (+0.75)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), SNY: 45.69 (-0.17), FOLD: 5.72 (-0.16)

Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), EXAS: 22.82 (-0.52), AFFX: 9.43 (-0.02)

Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), EXAS: 22.82 (-0.52)

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Mon Oct 20, 6:08AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 23.95 (+1.46)

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), RARE: 44.71 (-0.15), LGND: 53.94 (-0.97)

Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Infinity Pharmaceuticals (INFI) announced disappointing results from a phase IIa study on duvelisib.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), INFI: 13.01 (+0.87), ABBV: 61.50 (-1.21)

Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:30PM CDT
Health Canada issued a notice of compliance to Gilead's (GILD) Harvoni.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)

What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), ENZ: 4.94 (-0.13), EPZM: 23.75 (+0.19)

Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:30PM CDT
Alexion (ALXN) has filed a new drug application for asfotase alfa in Japan.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), LGND: 53.94 (-0.97)

Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), AGIO: 72.06 (-11.03), CELG: 106.45 (-0.69)

GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:48PM CDT
GW Pharmaceuticals (GWPH) announced disappointing results from a phase IIa study on GWP42003.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GWPH: 73.97 (-0.41), LGND: 53.94 (-0.97)

Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), NVAX: 4.95 (-0.20)

Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 3:30PM CDT
Alnylam Pharmaceuticals (ALNY) announced several study results on its pipeline candidates.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)

Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:45PM CDT
Alnylam (ALNY) revealed encouraging initial results from an ongoing phase II study on patisiran.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)

Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), PLX: 2.04 (-0.01), EPZM: 23.75 (+0.19)

Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), FCSC: 2.73 (+0.06), EPZM: 23.75 (+0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hisense Showcases AI in Everyday Living at IFA 2026

Hisense's Vision: An AI Utopia for Home Take this in: Hisense is cooking something bold at IFA 2026. They're pushing the envelope by integrating AI into our daily grind, promising to change the way we interact with the spaces that matter most. No more just dreaming about futuristic homes—these guys seem dead set on making them our everyday reality. Connected...

Tuya Smart's AI Innovations Steal the Spotlight at IFA

AI Taking Center Stage at IFA 2026 Amidst the chaos of tech exhibitions, something caught my attention—Tuya Smart's push in making AI a household name. Now, you might wonder why I’m bringing this up. Well, because it's not your typical flashy gadget talk. This is about Tuya parading their latest breakthroughs like a peacock at the world's stage, IFA 2026 in Berlin,...

Testing Grounds: Navigating PRN Test Insights

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Roborock Fuels Market Surge with 27.6% Revenue Boost

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Consumer365 Lauds Happy Head's Custom Hair Treatments

Revolutionizing Hair Loss Treatment The world of hair growth solutions is transforming right before our eyes. Thanks to the folks over at Happy Head and their customizable, dermatologist-prescribed treatments, the days of one-size-fits-all are ending. Consumer365 recently took a dive into Happy Head's model, giving their nod of approval to its personalized approach....

Penetron Strengthens Midwest, Central USA Support Team

Expansion of Penetron's Engineering Support Eyes are on the Midwest and Central USA as Penetron makes a strategic move to bolster their technical support dream team. They've snagged Sean Allison, a heavyweight with more than three decades' worth of grit and know-how from the construction battlefield. Sean, now stationed in the heart of America's Dairyland—Green Bay,...

Plumbing Pitfalls: When Water Heater Noises Spell Trouble

Understanding the Clamor from Your Water Heater The hustle and bustle of everyday life often drown out the less important noises. But when your water heater starts making a ruckus, maybe it's time to listen. From the keen ears of Jared Voss, a plumbing expert with his roots dug deep in Clinton, Iowa, we get the lowdown on what these noises could mean for your plumbing....

Nocpix's Evolution: New Thermal Riflescope Unveiled

Raising the Thermal Image Bar When Nocpix, known for cutting-edge electro-optical tech, teases a new thermal riflescope, it's time for hunters to perk up. This ain't just another gadget. We're talking about equipment that elevates precision and brings an edge to the field. Scheduled for hunters who mean business, this next-gen scope is destined to redefine what it means...

Shenzhen Media Push: Shaping Asia-Pacific's Future

A Metamorphosis in Shenzhen You ever hear about a place that rockets from obscurity to global significance in the blink of an eye? Well, Shenzhen, China is that place. Forty years ago, it was just a quaint fishing village. Fast forward a few decades, and you've got yourself an international powerhouse—a testament to China's rapid development strategy. Shenzhen is now...

UGREEN's AI Hub: Privacy-First Tech for Smart Homes

UGREEN's Big AI Leap In the bustling scene of home tech evolution, UGREEN's throwing its hat in the ring with its latest offerings. They've just rolled out the UGREEN HomeAgent series, aiming to redefine what we think of when it comes to smart living. UGREEN, usually known for its tech gadgets, is diving headfirst into the smart home pool. These local AI hubs blend tech...